Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Interferon Signature in Cancer Patients Treated With Anti-CTLA-4 and Anti-PD-1/PD-L1 Therapies: A Multicenter, Prospective, Observational Cohort Study Comparing Cancer Patients and Non-Cancer Patients With Systemic Autoimmune Diseases

NCT07249060 is registered in ClinicalTrials.gov with Hospital Universitario Araba as lead sponsor.

NCT NCT07249060
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07249060 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Interferon Signature in Cancer Patients Treated With Anti-CTLA-4 and Anti-PD-1/PD-L1 Therapies: A Multicenter, Prospective, Observational Cohort Study Comparing Cancer Patients and Non-Cancer Patients With Systemic Autoimmune Diseases
Lead sponsor
Hospital Universitario Araba
Phase
Observational
Overall status
Recruiting
Start date
January 8, 2024
Completion date
December 31, 2026
Enrollment
300 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

immune-related adverse events, inflammatory myopathies, lupus erythematosus, systemic, sjogren syndrome, solid tumors, systemic sclerosis (ssc)